Multivariate analysis: protective factors and risk factors for damage accrual over the follow-up
OR | 95% CI | p Value | |
(A) Baseline predictors and LLDAS | |||
≥5 Consecutive year LLDAS | 0.071 | 0.023 to 0.217 | <0.001 |
4 Consecutive year LLDAS | 0.122 | 0.034 to 0.443 | 0.001 |
3 Consecutive year LLDAS | 0.252 | 0.075 to 0.842 | 0.025 |
2 Consecutive year LLDAS | 0.279 | 0.085 to 0.920 | 0.036 |
1-Year LLDAS | 0.899 | 0.232 to 3.480 | 0.877 |
Age | 1.038 | 1.015 to 1.062 | 0.001 |
Mycophenolate | 2.173 | 1.062 to 4.446 | 0.034 |
Antiphospholipid antibody syndrome | 4.008 | 1.648 to 9.749 | 0.002 |
Cumulative PDN dose, g | 1.016 | 1.003 to 1.033 | 0.049 |
(B) Baseline predictors, LLDAS and remission | |||
≥2 consecutive year remission | 0.076 | 0.023 to 0.250 | <0.001 |
Age | 1.045 | 1.021 to 1.069 | 0.001 |
Skin involvement | 2.303 | 0.961 to 5.516 | 0.061 |
Mycophenolate | 2.160 | 1.044 to 4.470 | 0.038 |
Antiphospholipid antibody syndrome | 2.928 | 1.205 to 7.114 | 0.018 |
Cumulative PDN dose, g | 1.021 | 1.005 to 1.037 | 0.011 |
Variables entered in the multivariate analysis A were duration of LLDAS (categorical variable with six levels) and the following baseline characteristics: age, disease duration, SDI, mean SLEDAI-2K, skin involvement, vasculitis, use of mycophenolate and antimalarials, mean prednisone dose, APS and cumulative prednisone dose.
Variables entered in the multivariate analysis B were remission (considered as a dichotomous variable with two levels: remission lasting ≥2 consecutive years vs remission lasting <2 years), LLDAS (considered as a dichotomous variable with two levels: LLDAS lasting ≥2 consecutive years vs LLDAS lasting <2 years), and the following variables at baseline: age, disease duration, cumulative prednisone dose, SDI, APS, mean SLEDAI-2K, skin involvement and vasculitis, use of mycophenolate, cyclophosphamide and antimalarials, and mean prednisone dose.
Significant variables are given in bold.
LLDAS, lupus low disease activity state; PDN, prednisone.